Is Johnson & Johnson under Heavy Pressure?

Johnson & Johnson successfully beat earnings forecasts, its sales ticked up 4% and the company also increased its guidance. Yet the stock is flat. I guess most of the investors are uncertain about the future of J&J, considering the fact that Pfizer (PFE) will launch a cheaper version of J&J's immune drug Remicade. Looks like J&J is already feeling the pressure.